5 Dec 2022

Cystic fibrosis patients pleased with Trikafta funding

From Morning Report, 6:39 am on 5 December 2022

Pharmac has reached a provisional agreement to fund Trikafta, a cystic fibrosis drug which has been found to extend life expentancy by 27 years.

Cystic fibrosis is a terminal condition that affects about 540 people in New Zealand.

Previously, the drug cost patients $330,000 per year, putting it far out of reach for most. 

Cystic Fibrosis NZ chief executive Lisa Burns spoke to Corin Dann.